论文部分内容阅读
目的探讨静脉推注免疫球蛋白(IVIG)对婴幼儿重症肺炎的治疗效果。方法将符合婴幼儿重症肺炎诊断标准的患儿116例随机分成对照组和IVIG治疗组,IVIG用量0.4g/(kg·d),连用3d。结果IVIG治疗组在体温恢复、呼吸困难、咳嗽、喘息、肺部啰音消失、心力衰竭纠正、住院天数等方面明显优于对照组(P<0.01)。IgG浓度由治疗前的8.64±1.65升高为治疗后的12.06±1.88(P<0.05),IgA、IgM治疗前后无明显变化(P>0.05)。结论IVIG治疗婴幼儿重症肺炎有较好疗效,而且安全。
Objective To investigate the therapeutic effect of intravenous immunoglobulin (IVIG) on severe pneumonia in infants and children. Methods One hundred and sixty-six children diagnosed with severe pneumonia in infants and young children were randomly divided into control group and IVIG treatment group. The dosage of IVIG was 0.4g / (kg · d) for 3d. Results IVIG treatment group was significantly better than the control group (P <0.01) in the aspects of body temperature recovery, dyspnea, cough, wheezing, disappearance of pulmonary rales, correction of heart failure and days of hospitalization. The IgG concentration increased from 8.64 ± 1.65 before treatment to 12.06 ± 1.88 after treatment (P <0.05), but there was no significant change (P> 0.05) before and after IgA and IgM treatment. Conclusion IVIG treatment of severe pneumonia in infants and children have a good effect, but also safe.